Bedaquiline A Novel Promising Discovery in Multidrug-Resistant Tuberculosis
After acquired immunodeficiency syndrome (AIDS), tuberculosis (TB) is the leading cause of death worldwide due to a single infectious agent. Recently, drug-resistant strains of mycobacterium tuberculosis reported more horrible version of tuberculosis. There is threatful increase in multidrug resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) all over the world, so better treatment options are needed to control the global MDR-TB and XDR-TB epidemic. Bedaquiline, a diarylquinoline has a unique mechanism of action i.e. causes inhibition of the proton pump activity of the ATP synthase in mycobacterium tuberculosis and targets the energy metabolism. It acts as a promising new agent in patients with MDR-TB came in market recently. Bedaquiline can be combined with antituberculosis and antiretroviral agents. The drug showed good oral absorption, long terminal half-life and is metabolized mainly by cytochrome 450P3A4. It is recently been approved by U.S. Food and Drug Administration on 28th December, 2012 for treating multi drug resistant TB (MDR-TB) in adults ≥18 years. It seems to be good option for multidrug-resistant tuberculosis patients as it has earlier and sustained antitubercular action, shorten duration of treatment, less chances of resistance and better safety as compared to existing second line drugs. Long term studies are needed to explore its safety.